SP Scientific Licenses Praxair's ControLyo Nucleation Technology
SP Scientific (Gardiner, NY) has signed a license agreement to use Praxair's (Danbury, CT) ControLyo nucleation-on-demand technology, which provides pharmaceutical and biotechnology companies with control over the freeze-drying process for drug developmental efforts.
SP Scientific (Gardiner, NY) has signed a license agreement to use Praxair's (Danbury, CT) ControLyo nucleation-on-demand technology, which provides pharmaceutical and biotechnology companies with control over the freeze-drying process for drug developmental efforts.
The ControLyo technology was specifically developed to control the freezing step of lyophilization. In traditional lyophilization, the freezing step is uncontrolled because of the random nature of the nucleation or crystal-forming process. The ControLyo technology, however, controls the nucleation temperature to within 1 °C of its freezing point, which improves product uniformity, quality, and yield, and can reduce cycle times by as much as 40%.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
